Jay Tibbitts

4.2k total citations
47 papers, 2.3k citations indexed

About

Jay Tibbitts is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Jay Tibbitts has authored 47 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 33 papers in Radiology, Nuclear Medicine and Imaging and 10 papers in Immunology. Recurrent topics in Jay Tibbitts's work include Monoclonal and Polyclonal Antibodies Research (30 papers), HER2/EGFR in Cancer Research (25 papers) and Biosimilars and Bioanalytical Methods (9 papers). Jay Tibbitts is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (30 papers), HER2/EGFR in Cancer Research (25 papers) and Biosimilars and Bioanalytical Methods (9 papers). Jay Tibbitts collaborates with scholars based in United States, United Kingdom and Switzerland. Jay Tibbitts's co-authors include Sandhya Girish, Mark X. Sliwkowski, Kedan Lin, Scott N. Holden, Howard A. Burris, Shanu Modi, Gail D. Lewis Phillips, Douglas D. Leipold, Ben‐Quan Shen and Leslie A. Khawli and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Jay Tibbitts

46 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jay Tibbitts United States 22 1.6k 1.5k 646 242 177 47 2.3k
Dennis R. Benjamin United States 18 1.2k 0.8× 1.0k 0.7× 1.0k 1.6× 306 1.3× 87 0.5× 41 2.3k
Nicole M. Okeley United States 22 1.4k 0.9× 1.4k 0.9× 1.2k 1.9× 316 1.3× 105 0.6× 38 2.8k
Wayne C. Widdison United States 17 1.8k 1.1× 1.7k 1.1× 1.1k 1.6× 219 0.9× 90 0.5× 34 2.8k
Rajeeva Singh United States 22 940 0.6× 801 0.5× 872 1.3× 118 0.5× 83 0.5× 43 2.0k
Agamemnon A. Epenetos United Kingdom 30 665 0.4× 1.4k 0.9× 1.1k 1.6× 407 1.7× 250 1.4× 84 2.5k
Katherine R. Kozak United States 24 760 0.5× 674 0.4× 965 1.5× 342 1.4× 126 0.7× 39 2.0k
Brian A. Mendelsohn United States 26 1.5k 0.9× 1.5k 1.0× 1.0k 1.6× 151 0.6× 78 0.4× 39 2.6k
Sandhya Girish United States 30 3.1k 2.0× 2.4k 1.6× 879 1.4× 561 2.3× 424 2.4× 105 4.1k
Maarten L. Janmaat Netherlands 17 1.3k 0.8× 726 0.5× 1.0k 1.6× 567 2.3× 525 3.0× 28 2.4k
Alan Berezov United States 19 721 0.5× 465 0.3× 1000 1.5× 293 1.2× 189 1.1× 33 1.8k

Countries citing papers authored by Jay Tibbitts

Since Specialization
Citations

This map shows the geographic impact of Jay Tibbitts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay Tibbitts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay Tibbitts more than expected).

Fields of papers citing papers by Jay Tibbitts

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay Tibbitts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay Tibbitts. The network helps show where Jay Tibbitts may publish in the future.

Co-authorship network of co-authors of Jay Tibbitts

This figure shows the co-authorship network connecting the top 25 collaborators of Jay Tibbitts. A scholar is included among the top collaborators of Jay Tibbitts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay Tibbitts. Jay Tibbitts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brennan, Frank R., Laura Andrews, Antonio R. Arulanandam, et al.. (2018). Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges. Regulatory Toxicology and Pharmacology. 98. 98–107. 9 indexed citations
2.
Ulrich, Peter, Andreas Baumann, Adam Hey, et al.. (2018). Biotherapeutics in non-clinical development: Strengthening the interface between safety, pharmacokinetics-pharmacodynamics and manufacturing. Regulatory Toxicology and Pharmacology. 94. 91–100. 6 indexed citations
3.
Tibbitts, Jay, et al.. (2017). Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1. The AAPS Journal. 19(6). 1715–1734. 26 indexed citations
4.
Baumann, Andreas, Sven Kronenberg, Lolke de Haan, et al.. (2016). Non-clinical Safety Evaluation of Biotherapeutics – Challenges, Opportunities and new Insights. Regulatory Toxicology and Pharmacology. 80. S1–S14. 15 indexed citations
5.
Shen, Ben‐Quan, Daniela Bumbaca, Ola M. Saad, et al.. (2015). Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats. Drug Metabolism Letters. 9(2). 119–131. 17 indexed citations
6.
7.
Brennan, Frank R., Andreas Baumann, Lolke de Haan, et al.. (2015). Nonclinical safety testing of biopharmaceuticals – Addressing current challenges of these novel and emerging therapies. Regulatory Toxicology and Pharmacology. 73(1). 265–275. 13 indexed citations
8.
Erickson, Hans K., Gail D. Lewis Phillips, Douglas D. Leipold, et al.. (2014). Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates. Cancer Chemotherapy and Pharmacology. 74(5). 969–980. 22 indexed citations
9.
Bilic, Sanela, Douglas D. Leipold, William Mallet, et al.. (2013). American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates. mAbs. 5(1). 5–12. 10 indexed citations
10.
Wong, Harvey, Edna F. Choo, Bruno Alicke, et al.. (2012). Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response. Clinical Cancer Research. 18(14). 3846–3855. 96 indexed citations
11.
Lin, Kedan & Jay Tibbitts. (2012). Pharmacokinetic Considerations for Antibody Drug Conjugates. Pharmaceutical Research. 29(9). 2354–2366. 98 indexed citations
12.
Shen, Ben‐Quan, Daniela Bumbaca, Ola M. Saad, et al.. (2012). Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism. Current Drug Metabolism. 13(7). 901–910. 92 indexed citations
13.
Junutula, Jagath R., Kelly M. Flagella, Richard Graham, et al.. (2010). Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. Clinical Cancer Research. 16(19). 4769–4778. 214 indexed citations
14.
Krop, Ian E., Muralidhar Beeram, Shanu Modi, et al.. (2010). Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 28(16). 2698–2704. 437 indexed citations
15.
Tibbitts, Jay, et al.. (2010). Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals. Regulatory Toxicology and Pharmacology. 58(2). 243–251. 25 indexed citations
16.
Jumbe, Nelson L. ‘Shasha’, Xin Yan, Douglas D. Leipold, et al.. (2010). Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. Journal of Pharmacokinetics and Pharmacodynamics. 37(3). 221–242. 90 indexed citations
17.
Leipold, Douglas D., Jakub Baudys, Ola M. Saad, et al.. (2007). Development of a pharmacokinetic model examining trastuzumab-MCC-DM1, MCC-DM1 and DM1 in normal rats. Molecular Cancer Therapeutics. 6. 1 indexed citations
18.
Leipold, Douglas D., Nelson L. ‘Shasha’ Jumbe, Debra L. Dugger, et al.. (2007). Trastuzumab-MC-vc-PAB-MMAF: The effects of the Drug:Antibody Ratio (DAR) on efficacy, toxicity and pharmacokinetics.. Cancer Research. 67. 1551–1551. 3 indexed citations
19.
Li, Jin, Brian S. Bronk, John P. Dirlam, et al.. (2007). In vitro and in vivo profile of 5-[(4′-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity. Bioorganic & Medicinal Chemistry Letters. 17(7). 1996–1999. 13 indexed citations
20.
Tibbitts, Jay, et al.. (2000). Plasma Pharmacokinetics and Tissue Biodistribution of Boron Following Administration of a Boronated Porphyrin in Dogs. Journal of Pharmaceutical Sciences. 89(4). 469–477. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dennis R. Benjamin Breakdown of academic impact, for papers by Nicole M. Okeley Breakdown of academic impact, for papers by Wayne C. Widdison Breakdown of academic impact, for papers by Rajeeva Singh Breakdown of academic impact, for papers by Agamemnon A. Epenetos Breakdown of academic impact, for papers by Katherine R. Kozak Breakdown of academic impact, for papers by Brian A. Mendelsohn Breakdown of academic impact, for papers by Sandhya Girish Breakdown of academic impact, for papers by Maarten L. Janmaat Breakdown of academic impact, for papers by Alan Berezov
Rankless by CCL
2026